Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

MediciNova

Nasdaq:MNOV
Snowflake Description

Excellent balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MNOV
Nasdaq
$144M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The last earnings update was 44 days ago. More info.


Add to Portfolio Compare Print
  • MediciNova has significant price volatility in the past 3 months.
MNOV Share Price and Events
7 Day Returns
10.1%
NasdaqGM:MNOV
5.2%
US Biotechs
10.5%
US Market
1 Year Returns
-60.4%
NasdaqGM:MNOV
0%
US Biotechs
-11.5%
US Market
MNOV Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
MediciNova (MNOV) 10.1% -20.6% -49.5% -60.4% -45.2% -4.9%
US Biotechs 5.2% -6.5% -8.7% 0% 6.2% -10.4%
US Market 10.5% -15.4% -21.4% -11.5% 5.4% 18.1%
1 Year Return vs Industry and Market
  • MNOV underperformed the Biotechs industry which returned 0% over the past year.
  • MNOV underperformed the Market in United States of America which returned -11.5% over the past year.
Price Volatility
MNOV
Industry
5yr Volatility vs Market
Related Companies

MNOV Value

 Is MediciNova undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of MediciNova to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for MediciNova.

NasdaqGM:MNOV Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 2 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.9%
Perpetual Growth Rate 10-Year US Government Bond Rate 1.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGM:MNOV
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 1.7%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.2
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.2 (1 + (1- 21%) (0.28%))
1.136
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.14
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.74% + (1.136 * 5.44%)
7.92%

Discounted Cash Flow Calculation for NasdaqGM:MNOV using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for MediciNova is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

NasdaqGM:MNOV DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.92%)
2020 -13.92 Analyst x1 -12.89
2021 -6.18 Analyst x1 -5.31
2022 4.78 Analyst x1 3.80
2023 43.15 Analyst x1 31.81
2024 42.93 Analyst x1 29.33
2025 47.88 Est @ 11.53% 30.31
2026 52.00 Est @ 8.59% 30.50
2027 55.39 Est @ 6.54% 30.11
2028 58.22 Est @ 5.1% 29.32
2029 60.60 Est @ 4.09% 28.28
Present value of next 10 years cash flows $195.00
NasdaqGM:MNOV DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $60.60 × (1 + 1.74%) ÷ (7.92% – 1.74%)
$997.80
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $997.80 ÷ (1 + 7.92%)10
$465.66
NasdaqGM:MNOV Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $195.00 + $465.66
$660.66
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $660.66 / 43.96
$15.03
NasdaqGM:MNOV Discount to Share Price
Calculation Result
Value per share (USD) From above. $15.03
Current discount Discount to share price of $3.28
= -1 x ($3.28 - $15.03) / $15.03
78.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price MediciNova is available for.
Intrinsic value
>50%
Share price is $3.28 vs Future cash flow value of $15.03
Current Discount Checks
For MediciNova to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • MediciNova's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • MediciNova's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for MediciNova's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are MediciNova's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:MNOV PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-0.30
NasdaqGM:MNOV Share Price ** NasdaqGM (2020-03-27) in USD $3.28
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.4x
United States of America Market PE Ratio Median Figure of 2,939 Publicly-Listed Companies 12.96x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of MediciNova.

NasdaqGM:MNOV PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:MNOV Share Price ÷ EPS (both in USD)

= 3.28 ÷ -0.30

-10.94x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • MediciNova is loss making, we can't compare its value to the US Biotechs industry average.
  • MediciNova is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does MediciNova's expected growth come at a high price?
Raw Data
NasdaqGM:MNOV PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -10.94x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
58.5%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.96x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for MediciNova, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on MediciNova's assets?
Raw Data
NasdaqGM:MNOV PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $1.71
NasdaqGM:MNOV Share Price * NasdaqGM (2020-03-27) in USD $3.28
United States of America Biotechs Industry PB Ratio Median Figure of 429 Publicly-Listed Biotechs Companies 2.53x
United States of America Market PB Ratio Median Figure of 5,148 Publicly-Listed Companies 1.26x
NasdaqGM:MNOV PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:MNOV Share Price ÷ Book Value per Share (both in USD)

= 3.28 ÷ 1.71

1.92x

* Primary Listing of MediciNova.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • MediciNova is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess MediciNova's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. MediciNova has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

MNOV Future Performance

 How is MediciNova expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
58.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is MediciNova expected to grow at an attractive rate?
  • MediciNova's earnings growth is expected to exceed the low risk savings rate of 1.7%.
Growth vs Market Checks
  • MediciNova's earnings growth is expected to exceed the United States of America market average.
  • Unable to compare MediciNova's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:MNOV Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:MNOV Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 58.5%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:MNOV Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:MNOV Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 77 44 43 1
2023-12-31 84 44 49 1
2022-12-31 13 5 -6 2
2021-12-31 7 -5 -11 2
2020-12-31 0 -13 -15 2
2020-03-28
NasdaqGM:MNOV Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 -9 -13
2019-09-30 -8 -11
2019-06-30 -8 -16
2019-03-31 -8 -15
2018-12-31 -9 -15
2018-09-30 -9 -16
2018-06-30 -9 -13
2018-03-31 -8 -13
2017-12-31 -7 -11
2017-09-30 -7 -11
2017-06-30 -7 -10
2017-03-31 -7 -11

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • MediciNova's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if MediciNova is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:MNOV Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from MediciNova Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:MNOV Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31
2023-12-31 1.13 1.13 1.13 1.00
2022-12-31 -0.11 0.14 -0.35 2.00
2021-12-31 -0.22 -0.10 -0.34 2.00
2020-12-31 -0.34 -0.34 -0.34 1.00
2020-03-28
NasdaqGM:MNOV Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -0.30
2019-09-30 -0.26
2019-06-30 -0.37
2019-03-31 -0.35
2018-12-31 -0.36
2018-09-30 -0.40
2018-06-30 -0.34
2018-03-31 -0.35
2017-12-31 -0.32
2017-09-30 -0.32
2017-06-30 -0.29
2017-03-31 -0.31

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • MediciNova is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess MediciNova's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
MediciNova has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

MNOV Past Performance

  How has MediciNova performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare MediciNova's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • MediciNova does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare MediciNova's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare MediciNova's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
MediciNova's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from MediciNova Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:MNOV Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -12.94 7.95 6.08
2019-09-30 -11.17 7.88 4.42
2019-06-30 -15.57 11.04 5.64
2019-03-31 -14.83 10.35 5.55
2018-12-31 -14.68 9.96 5.63
2018-09-30 -16.07 11.99 6.51
2018-06-30 -13.05 9.86 5.41
2018-03-31 -12.69 9.74 4.93
2017-12-31 -11.16 8.86 4.17
2017-09-30 -11.01 7.40 3.66
2017-06-30 -10.09 6.83 3.28
2017-03-31 -10.50 7.17 3.34
2016-12-31 -10.87 7.42 3.46
2016-09-30 -12.15 8.34 3.84
2016-06-30 -10.92 7.39 3.54
2016-03-31 -10.01 6.63 3.37
2015-12-31 -8.85 5.81 3.02
2015-09-30 -8.49 5.58 2.89
2015-06-30 -9.22 6.03 3.19
2015-03-31 -9.06 5.84 3.23
2014-12-31 -9.20 5.96 3.26
2014-09-30 6.00 -3.40 6.00 3.41
2014-06-30 6.00 -3.30 6.00 3.31
2014-03-31 6.00 -3.96 6.55 3.42
2013-12-31 6.00 -4.03 6.66 3.37
2013-09-30 0.04 -9.88 6.70 3.21
2013-06-30 0.12 -10.02 6.82 3.29
2013-03-31 0.61 -9.51 6.27 3.83

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if MediciNova has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if MediciNova has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if MediciNova improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess MediciNova's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
MediciNova has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

MNOV Health

 How is MediciNova's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up MediciNova's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • MediciNova is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • MediciNova's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of MediciNova's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • MediciNova has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from MediciNova Company Filings, last reported 2 months ago.

NasdaqGM:MNOV Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 74.89 0.00 63.79
2019-09-30 74.35 0.00 62.87
2019-06-30 73.18 0.00 61.74
2019-03-31 75.04 0.00 63.21
2018-12-31 73.11 0.00 62.31
2018-09-30 73.55 0.00 62.44
2018-06-30 75.59 0.00 64.16
2018-03-31 75.57 0.00 62.94
2017-12-31 38.64 0.00 27.99
2017-09-30 34.72 0.00 24.54
2017-06-30 33.39 0.00 22.89
2017-03-31 32.75 0.00 21.64
2016-12-31 34.53 0.00 24.12
2016-09-30 35.75 0.00 24.97
2016-06-30 37.37 0.00 26.57
2016-03-31 39.14 0.00 27.62
2015-12-31 32.75 0.00 22.08
2015-09-30 34.63 0.00 23.61
2015-06-30 19.95 0.00 8.58
2015-03-31 20.95 0.00 9.07
2014-12-31 22.01 0.00 11.67
2014-09-30 22.98 0.00 11.94
2014-06-30 24.80 0.00 13.50
2014-03-31 26.65 0.00 14.78
2013-12-31 25.43 0.00 6.70
2013-09-30 21.45 0.00 10.66
2013-06-30 22.95 0.00 12.02
2013-03-31 14.25 0.00 3.03
  • MediciNova has no debt.
  • MediciNova currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • MediciNova has sufficient cash runway for more than 3 years based on current free cash flow.
  • Unable to confirm if MediciNova has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess MediciNova's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. MediciNova has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

MNOV Dividends

 What is MediciNova's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from MediciNova dividends.
If you bought $2,000 of MediciNova shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate MediciNova's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate MediciNova's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:MNOV Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1949 Stocks 3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2%
United States of America Top 25% Dividend Yield 75th Percentile 5.4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:MNOV Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-03-28

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as MediciNova has not reported any payouts.
  • Unable to verify if MediciNova's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of MediciNova's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as MediciNova has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess MediciNova's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can MediciNova afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. MediciNova has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

MNOV Management

 What is the CEO of MediciNova's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Yuichi Iwaki
COMPENSATION $2,853,305
AGE 69
TENURE AS CEO 14.5 years
CEO Bio

Dr. Yuichi Iwaki, M.D., Ph.D. is a Co-Founder of MediciNova Inc. and has been its Chief Executive Officer and President since March 2006. Dr. Iwaki is a Partner of Biotech Healthcare Partners, Inc. He was an Advisor of JAFCO Co., Ltd. He has been advising pharmaceutical companies and venture capital funds regarding research and investment strategies for over 30 years and is a Board Member of several biotechnology companies. He served as an Acting Chief Financial Officer and Acting Chief Accounting Officer of MediciNova Inc. from November 8, 2013 to April 2014. He served as an Acting Chief Executive Officer of MediciNova since September 2005 and its Acting Chief Financial Officer from September 2005 to November 2011. He served as the Chairman of MediciNova Inc., from September 26, 2000 to March 30, 2007, became its Executive Chairman in July 2005. He was a Director of Avigen since November 1994 until 2008 Dr. Iwaki serves as a Director at Biotech Healthcare Partners, Inc. He has been an Executive Director of MediciNova since September 26, 2000. From September 2001 until January 2007, Dr. Iwaki also served as consultant at MediciNova Inc. in connection with financing transactions and business development activities. He is a Director of the Transplantation Immunology and Immunogenetic Laboratory since 1992 and Intercept Pharmaceuticals, Inc. Dr. Iwaki is also a visiting professor at the Toho University School of Medicine. He is also a Member of Advisory Board of Two River Group Holdings, LLC. He served as a Director at Antyra, Inc. He has held three professorships at University of Southern California School of Medicine in the departments of urology, pathology and surgery since 1992. He is a Professor in the Department of Urology, Surgery and Pathology at Keck School of Medicine. In addition, Dr. Iwaki holds visiting professorships at the University of California, Irvine, School of Medicine; Nihon University School of Medicine, Kyushu University; and the Tokyo Women's Medical School in Japan. Prior to joining the University of Southern California School of Medicine faculty in 1992, he held professorships at the University of Pittsburgh in the Departments of Surgery and Pathology from 1989 through 1991. Dr. Iwaki is the author of more than 200 peer-reviewed publications and more than 40 books. He received a Ph.D. and an M.D. from Sapporo Medicine School in Sapporo.

CEO Compensation
  • Yuichi's compensation has increased whilst company is loss making.
  • Yuichi's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the MediciNova management team in years:

8.5
Average Tenure
53
Average Age
  • The average tenure for the MediciNova management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Yuichi Iwaki

TITLE
Co-Founder
COMPENSATION
$3M
AGE
69
TENURE
14.5 yrs

Kazuko Matsuda

TITLE
Chief Medical Officer & Director
COMPENSATION
$2M
AGE
53
TENURE
8.5 yrs

Carla Reyes

TITLE
Chief Financial Officer
AGE
47
TENURE
1.8 yrs

John O’Neil

TITLE
Controller
Board of Directors Tenure

Average tenure and age of the MediciNova board of directors in years:

6.2
Average Tenure
58.5
Average Age
  • The tenure for the MediciNova board of directors is about average.
Board of Directors

Jeff Himawan

TITLE
Independent Chairman
AGE
54
TENURE
13 yrs

Yuichi Iwaki

TITLE
Co-Founder
COMPENSATION
$3M
AGE
69
TENURE
19.5 yrs

Kazuko Matsuda

TITLE
Chief Medical Officer & Director
COMPENSATION
$2M
AGE
53
TENURE
0.7 yrs

Yutaka Kobayashi

TITLE
Independent Director
COMPENSATION
$110K
AGE
55
TENURE
6.4 yrs

Yoshio Ishizaka

TITLE
Independent Director
COMPENSATION
$120K
AGE
79
TENURE
5.9 yrs

Hideki Nagao

TITLE
Independent Director
COMPENSATION
$120K
AGE
62
TENURE
2.3 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by MediciNova individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
16. Mar 20 Buy Kazuko Matsuda Individual 13. Mar 20 13. Mar 20 2,000 $3.62 $7,240
12. Mar 20 Buy Yuichi Iwaki Individual 12. Mar 20 12. Mar 20 20,000 $3.10 $62,000
X
Management checks
We assess MediciNova's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. MediciNova has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

MNOV News

Simply Wall St News

Should You Be Concerned About MediciNova, Inc.'s (NASDAQ:MNOV) Historical Volatility?

Given that it has a beta of 1.2, we can surmise that the MediciNova share price has been fairly sensitive to market volatility (over the last 5 years). … Because it takes less capital to move the share price of a small company like this, when a stock this size is actively traded it is quite often more sensitive to market volatility than similar large companies. … What this means for you: Beta only tells us that the MediciNova share price is sensitive to broader market movements.

Simply Wall St -

How Much Of MediciNova, Inc. (NASDAQ:MNOV) Do Insiders Own?

View our latest analysis for MediciNova NasdaqGM:MNOV Ownership Summary, May 10th 2019 What Does The Institutional Ownership Tell Us About MediciNova? … Insider Ownership Of MediciNova The definition of company insiders can be subjective, and does vary between jurisdictions. … Shareholders would probably be interested to learn that insiders own shares in MediciNova, Inc..

Simply Wall St -

Is MediciNova's (NASDAQ:MNOV) Share Price Gain Of 282% Well Earned?

(NASDAQ:MNOV) share price has had a bad week, falling 11%. … With zero revenue generated over twelve months, we MediciNova has proved its business plan yet. … So the share price itself impacts the value of the shares (as it determines the cost of capital).

Simply Wall St -

How MediciNova, Inc. (NASDAQ:MNOV) Can Impact Your Portfolio Volatility

Volatility is considered to be a measure of risk in modern finance theory. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … While we should keep in mind that Warren Buffett has cautioned that 'Volatility is far from synonymous with risk', beta is still a useful factor to consider.

Simply Wall St -

What Percentage Of MediciNova Inc (NASDAQ:MNOV) Shares Do Insiders Own?

Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … MediciNova is not a large company by global standards. … Our analysis of the ownership of the company, below, shows that.

Simply Wall St -

Is MediciNova Inc's (NASDAQ:MNOV) CEO Pay Justified?

Understanding how CEOs are incentivised to run and grow their company is an important aspect of investing in a stock. … This is because, if incentives are aligned, more value is created for shareholders which directly impacts your returns as an investor. … CEOs leading companies of similar size and profitability

Simply Wall St -

Should MediciNova Inc's (NASDAQ:MNOV) Recent Earnings Decline Worry You?

Analyzing MediciNova Inc's (NASDAQ:MNOV) track record of past performance is a valuable exercise for investors. … Today I will assess MNOV's recent performance announced on 31 March 2018 and compare these figures to its long-term trend and industry movements. … MNOV is loss-making, with the most recent trailing twelve-month earnings of -US$12.69m (from 31 March 2018), which compared to last year has become

Simply Wall St -

MediciNova Inc (NASDAQ:MNOV): Should The Future Outlook Worry You?

The latest earnings announcement MediciNova Inc's (NASDAQ:MNOV) released in December 2017 showed that losses became smaller relative to the prrior year's level - great news for investors Below, I've presented key growth figures on how market analysts predict MediciNova's earnings growth outlook over the next few years and whether the future looks brighter. … See our latest analysis for MediciNova Market analysts' consensus outlook for this coming year seems pessimistic, with earnings becoming even more negative, arriving at -US$14.71M in 2019. … Future Earnings: How does MNOV's growth rate compare to its peers and the wider market?

Simply Wall St -

Who Are The Major Shareholders Of MediciNova Inc (NASDAQ:MNOV)?

In this article, I'm going to take a look at MediciNova Inc’s (NASDAQ:MNOV) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors. … Although MNOV has a high institutional ownership, such stock moves, in the short-term, are more commonly linked to a particular type of active institutional investors – hedge funds. … Public Company Ownership Another important group of owners for potential investors in MNOV are other public companies that hold a stake of 3.42% in MNOV.

Simply Wall St -

Is MediciNova Inc (NASDAQ:MNOV) Cheap And High Growth?

However, analysts are not expecting this industry-beating trend to continue, with future growth expected to be -6.39% compared to the wider biotech sector growth hovering of 1.58%, next year. … As a future industry laggard in growth, MediciNova may be a cheaper stock relative to its peers. … Next Steps: MediciNova is a biotech industry laggard in terms of its future growth outlook.

Simply Wall St -

MNOV Company Info

Description

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. MediciNova, Inc. was founded in 2000 and is headquartered in La Jolla, California.

Details
Name: MediciNova, Inc.
MNOV
Exchange: NasdaqGM
Founded: 2000
$144,175,745
43,956,020
Website: http://medicinova.com
Address: MediciNova, Inc.
4275 Executive Square,
Suite 300,
La Jolla,
California, 92037,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM MNOV Common Stock Nasdaq Global Market US USD 09. Feb 2005
DB RMN Common Stock Deutsche Boerse AG DE EUR 09. Feb 2005
JASDAQ 4875 Common Stock TSE JASDAQ JP JPY 09. Feb 2005
Number of employees
Current staff
Staff numbers
8
MediciNova employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/28 03:27
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/03/16
Last earnings filing: 2020/02/13
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.